We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+1.2%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$392M
AUM Growth
-$18M
(-4.4%)
Cap. Flow
-$36.6M
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
63.12%
Holding
39
New
11
Increased
9
Reduced
9
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$24.1M |
| 2 |
Viatris
VTRS
|
+$23.2M |
| 3 |
CVS Health
CVS
|
+$22.9M |
| 4 |
Novartis
NVS
|
+$17.3M |
| 5 |
Abbott
ABT
|
+$17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$60.5M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$28.3M |
| 3 |
AGN.PRA
Allergan plc
AGN.PRA
|
+$28.1M |
| 4 |
Elevance Health
ELV
|
+$24.1M |
| 5 |
Encompass Health
EHC
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.53% |
| 2 | Financials | 6.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Theravance Biopharma
TBPH
$875M
| $4.79M | 1.22% |
171,800
-10,300
| -6% | -$305K |
|
27
Protagonist Therapeutics
PTGX
$8.79B
| $3.74M | 0.96% |
180,000
-41,000
| -19% | -$727K |
|
|
FOMX
28
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.27M | 0.58% |
377,397
-85,900
| -19% | -$517K |
|
29
Rocket Pharmaceuticals
RCKT
$359M
| $1.66M | 0.42% |
159,256
-36,225
| -19% | -$359K |
|
|
EXAS
30
PUT
DELISTED
Exact Sciences
EXAS
| $1.16M | 0.3% |
5,541
-652,459
| -99% | -$34.8M |
|
|
31
Elevance Health
ELV
$82B
| – | – |
-126,700
| Closed | -$24.1M |
|
32
Globus Medical
GMED
$10.7B
| – | – |
-329,400
| Closed | -$9.79M |
|
33
Insmed
INSM
$23B
| – | – |
-238,700
| Closed | -$7.45M |
|
34
Pediatrix Medical
MD
$2.18B
| – | – |
-153,000
| Closed | -$6.6M |
|
35
Universal Health Services
UHS
$9.78B
| – | – |
-61,200
| Closed | -$6.79M |
|
|
CLVS
36
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-112,400
| Closed | -$9.26M |
|
|
TSRO
37
DELISTED
TESARO, Inc.
TSRO
| – | – |
-219,500
| Closed | -$28.3M |
|
|
ESRX
38
DELISTED
Express Scripts Holding Company
ESRX
| – | – |
-108,901
| Closed | -$6.9M |
|
|
CORI
39
DELISTED
Corium International, Inc.
CORI
| – | – |
-445,166
| Closed | -$4.93M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q4 2017 Portfolio in Review
As of Q4 2017, Senzar Asset Management held 39 positions worth $392M, down 4.4% from $410M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Senzar Asset Management withdrew a net $36.6M in Q4 2017, closing 10 positions and reducing 9 holdings. Its most notable exit was TESARO, Inc., an estimated $28.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 81% a quarter earlier, followed by Financials.
Against the trend, Senzar Asset Management opened a new position in Aetna Inc worth $25.3M.
- Senzar Asset Management's largest Q4 2017 buy was Aetna Inc: 140,200 shares worth $25.3M.
- Senzar Asset Management added most to Ironwood Pharmaceuticals in Q4 2017, an estimated $14.7M increase.
- Senzar Asset Management's biggest Q4 2017 reduction was Halozyme, cutting an estimated $60.5M.
- Senzar Asset Management fully exited TESARO, Inc. in Q4 2017, selling an estimated $28.3M.
- Senzar Asset Management's ten largest holdings make up 63% of its $392M portfolio in Q4 2017.
- Senzar Asset Management opened 11 new positions and closed 10 in Q4 2017.
- Senzar Asset Management's portfolio value fell 4.4% quarter-over-quarter to $392M.
Based on Senzar Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.